Q3 EPS Estimates for AnaptysBio Raised by Leerink Partnrs

Key Points

• Leerink Partners has raised its Q3 2025 earnings estimate for AnaptysBio to ($0.84) per share, improving from the previous estimate of ($1.08).
• Analysts' ratings for AnaptysBio show a positive trend, with a consensus rating of "Moderate Buy" and a target price of $47.75.
• AnaptysBio reported a better-than-expected quarterly earnings result with an EPS of ($1.34), exceeding consensus estimates by $0.16.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Equities research analysts at Leerink Partnrs upped their Q3 2025 earnings per share estimates for AnaptysBio in a report issued on Wednesday, August 6th. Leerink Partnrs analyst D. Risinger now anticipates that the biotechnology company will post earnings of ($0.84) per share for the quarter, up from their prior estimate of ($1.08). The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio's Q4 2025 earnings at ($0.67) EPS, FY2025 earnings at ($3.97) EPS, FY2026 earnings at ($1.18) EPS, FY2027 earnings at ($2.66) EPS, FY2028 earnings at ($2.14) EPS and FY2029 earnings at ($0.92) EPS.

ANAB has been the topic of a number of other research reports. Wedbush upped their price objective on AnaptysBio from $40.00 to $45.00 and gave the stock an "outperform" rating in a report on Thursday, August 7th. Guggenheim reissued a "buy" rating and issued a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a report on Wednesday, May 28th. UBS Group reaffirmed a "neutral" rating and set a $20.00 price objective (up previously from $18.00) on shares of AnaptysBio in a research note on Tuesday. JPMorgan Chase & Co. increased their price objective on AnaptysBio from $42.00 to $80.00 and gave the company an "overweight" rating in a research note on Thursday, July 24th. Finally, HC Wainwright raised AnaptysBio from a "neutral" rating to a "buy" rating and increased their price objective for the company from $22.00 to $38.00 in a research note on Wednesday, June 4th. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $46.13.

AnaptysBio Trading Up 0.5%

Shares of AnaptysBio stock traded up $0.11 during trading hours on Monday, hitting $20.11. 432,780 shares of the company were exchanged, compared to its average volume of 776,004. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $41.31. The business has a 50-day moving average of $24.09 and a 200-day moving average of $20.52. The stock has a market capitalization of $563.08 million, a price-to-earnings ratio of -4.49 and a beta of -0.20.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.50) by $0.16. AnaptysBio had a negative return on equity of 366.98% and a negative net margin of 107.66%. The business had revenue of $22.26 million during the quarter, compared to analysts' expectations of $11.55 million.

Insiders Place Their Bets

In related news, Director Hollings Renton sold 20,925 shares of the stock in a transaction dated Wednesday, July 2nd. The stock was sold at an average price of $23.57, for a total transaction of $493,202.25. Following the transaction, the director directly owned 4,965 shares in the company, valued at approximately $117,025.05. This represents a 80.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Company insiders own 33.50% of the company's stock.

Hedge Funds Weigh In On AnaptysBio

Large investors have recently modified their holdings of the company. US Bancorp DE raised its holdings in shares of AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 979 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of AnaptysBio by 9,778.9% in the 1st quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 1,858 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of AnaptysBio by 131.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,697 shares of the biotechnology company's stock worth $36,000 after purchasing an additional 1,531 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in AnaptysBio in the 4th quarter valued at $40,000. Finally, Virtus ETF Advisers LLC lifted its stake in shares of AnaptysBio by 24.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company's stock worth $63,000 after purchasing an additional 936 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.